Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

This article was originally published in The Tan Sheet

Executive Summary

Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.

You may also be interested in...



Cell Vitals ‘Revolution’ Quelled? FDA Warns About Stem-Cell Claims

Claims promoting Cell Vitals’ ReLuma skin care line render the products unapproved drugs, FDA says. Marketed as “A Revolution in Stem Cell Skin Care,” the products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the firms says.

Cell Vitals ‘Revolution’ Quelled? FDA Warns About Stem-Cell Claims

Claims promoting Cell Vitals’ ReLuma skin care line render the products unapproved drugs, FDA says. Marketed as “A Revolution in Stem Cell Skin Care,” the products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the firms says.

FTC-L’Oreal Settlement Should Reverberate Across Industry – Attorneys

The recent action against L’Oreal sends a signal to industry that FTC is paying attention to their claims. In an interview with “The Rose Sheet,” attorneys from Edwards Wildman Palmer discuss the case’s implications and whether it heralds a new FTC focus on cosmetics.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel